IntelliGenome has received the FDA's Breakthrough Device Designation for its CRISPR-based TB Blood Test. This innovative test promises faster and more accurate tuberculosis diagnostics.

IntelliGenome has announced its collaboration with Yu Shing Bio-Tech, marking a significant advancement in tuberculosis diagnostics through the CRISPR-TB test in Taiwan.

IntelliGenome has received INVIMA approval for its innovative CRISPR-TB blood test and has partnered with Velez Lab for exclusive distribution in Colombia, enhancing tuberculosis diagnostics.

HOUSTON, July 28, 2026 /PRNewswire/ -- IntelliGenome, Inc., a leader in CRISPR-based molecular diagnostics, today announced the appointment of Yu Shing Bio-Tech Co., Ltd. as its exclusive distributor for Taiwan. Under the agreement, Yu Shing Bio-Tech will commercialize IntelliGenome's...

IntelliGenome has named SIMED S.A. as its exclusive distributor of the CRISPR-TB™ Blood Test in Peru and Ecuador, enhancing tuberculosis diagnostics in the region.

IntelliGenome's CRISPR-TB assay is designed to detect Mycobacterium tuberculosis complex cell-free DNA from blood.

IntelliGenome has appointed ILEX South Africa as the exclusive distributor for its CRISPR-TB diagnostics. This partnership aims to enhance TB detection in South Africa, a leader in TB research.

HOUSTON and JOHANNESBURG, July 20, 2026 /PRNewswire/ -- IntelliGenome, Inc., a biotechnology company developing CRISPR-based molecular diagnostics, today announced the appointment of ILEX South Africa (Pty) Ltd. as its exclusive distributor for CRISPR-TB® in South Africa. South Africa is...

The partnership aims to accelerate the evaluation, market development, and commercialization of a diagnostic test called CRISPR-TB.

Intelligenome will contribute its testing platform to an NIH-funded program centered on cell-free DNA tuberculosis detection from respiratory and blood samples.

News items for the week of Jan. 20, 2025.

IntelliGenome and CTR Scientific have partnered to advance CRISPR-TB testing in Mexico, aiming to enhance tuberculosis detection with innovative technology.

HOUSTON and BOGOTÁ, Colombia, June 29, 2026 /PRNewswire/ -- IntelliGenome, Inc., a molecular diagnostics company advancing next-generation tuberculosis detection technologies, today announced that Colombia's National Institute for Food and Drug Surveillance (INVIMA) has granted sanitary...

HOUSTON and MONTERREY, Mexico, June 15, 2026 /PRNewswire/ -- IntelliGenome, Inc. today announced a strategic partnership with CTR Scientific (Control Técnico y Representaciones S.A. de C.V.) to support the evaluation, commercialization, and future adoption of the CRISPR-TB Blood Test in...

HOUSTON, March 23, 2026 /PRNewswire/ -- Intelligenome, a global leader in CRISPR-based in vitro diagnostic (IVD) technology, is pleased to announce that it has entered into a research and development subaward agreement with Cornell University to support the development of a rapid,...